This study is examining the effectiveness of antibody drug tiragolumab with or without standard treatment for relapsed or unresponsive multiple myeloma or non-Hodgkin lymphoma. The main outcome would be the side effects experienced by patients 1 year after treatment.
Both multiple myeloma (MM) and non-Hodkin lymphoma (NHL) are types of blood cancers. Some patients respond to treatment such as chemotherapy. If the cancer returns, it is called relapsed disease. Some patients do not respond to treatment and this is called refractory disease. New treatments could help these patients. Currently, daratumumab (Darzalex) is used to treat patients with MM. Rituximab (Rituxan) is used to treat patients with NHL. A new antibody drug called tiragolumab may be able to help patients with relapsed or refractory MM or NHL.
The purpose of this study is to see if tiragolumab can improve the killing of MM or NHL cells with or without daratumumab (MM patients) or rituximab (NHL patients). The main outcome would be to see the number of patients who experience side effects 1 year after treatment.
Who are they looking for?
This study is recruiting 52 patients with relapsed or refractory MM or NHL. Patients with MM must have received treatment at least 3 times previously or do not qualify for other types of treatment. Patients with NHL must have not responded to at least two types of therapy and do not qualify for other highly effective treatments.
Patients who have received different types of therapy within 4 weeks of the study or stem cell transplant within 100 days starting cannot participate. Patients with autoimmune diseases or infections cannot participate. Patients with plasma cell leukemia or cancer in the brain cannot participate. Patients with NHL who have high calcium levels, cancer in the brain or those that can receive stem cell transplants cannot participate.
How will it work
There will be four groups in this study. Group A will include patients with MM who will receive tiragolumab by intravenous infusion. Group B will include patients with NHL who will receive tiragolumab. Group C will include patients with MM who will receive tiragolumab and daratumumab. Group D will include patients with NHL who will receive tiragolumab and rituximab.
All patients will be monitored for side effects for approximately 1 year. Patients will also be checked for the amount of tiragolumab in their blood, the effectiveness of treatment and allergic reactions to tiragolumab.